NEW YORK, April 25 - Biogen has licensed the Rosetta Resolver gene expression analysis system from Rosetta Inpharmatics, the companies said Wednesday.
Biogen will use the Resolver system to manage and analyze its gene expression data, the pharmaceutical company said in a statement. The companies did not disclose financial details of the deal.
"The latest version of the system is geared specifically to organizations like Biogen, with expertise in gene expression research and a need for high-throughput analysis of Affymetrix GeneChip and other types of microarray data," Stephen Friend, CEO of Rosetta Inpharmatics, said in a statement.
The Resolver system accepts data from a wide variety of expression profiling formats, including Affymetrix GeneChip and Agilent DNA microarrays, and applies proprietary error models to calculate statistics on the gene expression data. Rosetta released version 2.0 of the system last quarter and has granted Agilent Technologies exclusive distribution rights to it.Rosetta's other licensees for the Resolver include the Harvard Center for Genomic Research, Immunex, Paradigm Genetics, and GlaxoSmithKline. Rosetta has also penned deals to use the technology in collaboration with Abbott Labs, Gemini Genomics, Monsanto, and Sangamo Biosciences.